HIGH-VOLUME · SEX-BALANCED

dulaglutide Side Effects

dulaglutide (also sold as Trulicity) is HIGH-VOLUME in this FAERS book #88 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 58% of sex-coded reports are female (44,406 F / 32,394 M).

Data updated 2026-05-15

85,635
FAERS reports

FAERS voluntary reports, 2011 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

dulaglutide reporting skew - 58% of sex-coded reports are female (44,406 F / 32,394 M). Volume band HIGH-VOLUME #88 of 524 by FAERS report count; caseload CASELOAD.

High-report extract for dulaglutide (Trulicity): 85,635 FAERS rows (2011-2025). Top named reactions: NAUSEA, INJECTION SITE PAIN, BLOOD GLUCOSE INCREASED. Outcome stamps DEATH-MARKED · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2011–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.

NAUSEA leads 9,986 of 85,635 reports

NAUSEA
9,986
INJECTION SITE PAIN
9,796
BLOOD GLUCOSE INCREASED
9,762
DIARRHOEA
5,737
INCORRECT DOSE ADMINISTERED
5,444
VOMITING
5,413
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION
3,806
WEIGHT DECREASED
3,349
DECREASED APPETITE
3,153
INJECTION SITE HAEMORRHAGE
3,132
EXTRA DOSE ADMINISTERED
3,106
GLYCOSYLATED HAEMOGLOBIN INCREASED
2,906
FATIGUE
2,409
ACCIDENTAL UNDERDOSE
2,354
ABDOMINAL PAIN UPPER
2,321
MALAISE
2,051
CONSTIPATION
2,035
ABDOMINAL PAIN
2,018

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 44,406 (58%)
Male 32,394 (42%)
Unknown 11

Age peak 45-64 (17,698 reports)

0-17 127 (0%)
18-44 3,325 (9%)
45-64 17,698 (47%)
65-74 11,124 (29%)
75+ 5,637 (15%)

FAERS filings rising toward 2025

11
12
14
15
16
17
18
19
20
21
22
23
24
25

Reactions in Death Reports

Death appears on 1,580 reports (1.8% - MARKED). Reactions below co-occur in those rows only.

Reaction Reports
DEATH 722
PANCREATIC CARCINOMA 58
LACTIC ACIDOSIS 55
MYOCARDIAL INFARCTION 55
COVID-19 51
NAUSEA 47
PNEUMONIA 46
CARDIAC ARREST 42
VOMITING 42
DECREASED APPETITE 39
ACUTE KIDNEY INJURY 38
DIARRHOEA 36
CARDIO-RESPIRATORY ARREST 33
DYSPNOEA 31
MULTIPLE ORGAN DYSFUNCTION SYNDROME 30
PANCREATITIS 29
SEPSIS 28
FATIGUE 26
SEPTIC SHOCK 26

Reactions in Hospitalization Reports

Hospitalization mid-share (10,007, 11.7%). Co-reported reactions:

Reaction Reports
NAUSEA 1,419
VOMITING 1,402
DIARRHOEA 1,078
IMPAIRED GASTRIC EMPTYING 743
BLOOD GLUCOSE INCREASED 717
ABDOMINAL PAIN 676
DEHYDRATION 668
PANCREATITIS 585
CONSTIPATION 509
DECREASED APPETITE 502
ACUTE KIDNEY INJURY 471
FALL 394
WEIGHT DECREASED 378
DIABETIC KETOACIDOSIS 357
ABDOMINAL PAIN UPPER 330
DYSPNOEA 321
COVID-19 306
PNEUMONIA 291
FATIGUE 288
How to read dulaglutide FAERS figures (CASELOAD · DEATH-MARKED · HOSP-MID)

FAERS holds 85,635 voluntary reports linked to dulaglutide (Trulicity), 2011-2025. Death is listed on 1,580 (1.8%). Hospitalization appears on 10,007 (11.7%). Top co-reported indication: Product Used For Unknown Indication.

CASELOAD books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.

Read with dulaglutide

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.